Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OrbusNeich to validate bioengineered stent

This article was originally published in Clinica

Executive Summary

Just weeks after announcing it had CE-marked for sale in Europe the first bioengineered stent, Genous, Hong Kong firm OrbusNeich is pressing on with its clinical trial programme to substantiate the product's efficacy. The company has begun a global internet-based registry called e-HEALING, which will assess outcomes of 5,000 patients enrolled at over 100 centres; the device is currently only available through the registry. The registry is sufficiently large to generate the data needed to quantify the technology's safety profile, said the company. The company has also completed the design phase of an upcoming randomised trial, called HEALING III, which will involve angiographic follow up to compare Genous stents with bare metal stents both in conjunction with statin therapy. HEALING III is scheduled to start later this year or in early 2006.

You may also be interested in...

IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs

Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.

Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat

Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.

Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients

While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts